Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Buy" from Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) has received a consensus recommendation of "Buy" from the seven research firms that are currently covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $48.20.

Several analysts have issued reports on the stock. Ascendiant Capital Markets decreased their price objective on shares of Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating for the company in a research note on Tuesday, September 3rd. BTIG Research reissued a "buy" rating and set a $50.00 price target on shares of Outlook Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Finally, Chardan Capital reiterated a "buy" rating and set a $53.00 target price on shares of Outlook Therapeutics in a research report on Friday, August 16th.

Outlook Therapeutics Trading Up 0.5 %

NASDAQ:OTLK traded up $0.03 during midday trading on Wednesday, hitting $5.77. 97,130 shares of the company traded hands, compared to its average volume of 350,703. The firm has a market capitalization of $136.50 million, a P/E ratio of -0.50 and a beta of 0.62. The firm's fifty day moving average is $6.13 and its 200-day moving average is $7.19. Outlook Therapeutics has a 12-month low of $4.61 and a 12-month high of $13.32.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($1.06) by $0.23. On average, research analysts expect that Outlook Therapeutics will post -3.63 EPS for the current fiscal year.

Insider Transactions at Outlook Therapeutics

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were purchased at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the completion of the purchase, the chief financial officer now owns 5,946 shares in the company, valued at approximately $33,832.74. This trade represents a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 3.40% of the company's stock.

Institutional Investors Weigh In On Outlook Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC lifted its position in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock valued at $12,557,000 after buying an additional 221,510 shares during the last quarter. Rosalind Advisors Inc. lifted its position in Outlook Therapeutics by 44.3% during the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company's stock valued at $3,321,000 after acquiring an additional 138,225 shares during the last quarter. LVW Advisors LLC acquired a new stake in Outlook Therapeutics in the second quarter valued at approximately $352,000. Susquehanna Fundamental Investments LLC acquired a new stake in Outlook Therapeutics in the second quarter valued at approximately $303,000. Finally, Squarepoint Ops LLC purchased a new position in Outlook Therapeutics in the second quarter worth $232,000. Institutional investors own 11.20% of the company's stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.